| Literature DB >> 24330678 |
Lifu Sheng, Iryna Leshchyns'ka, Vladimir Sytnyk1.
Abstract
Cell adhesion molecules (CAMs) play indispensable roles in the developing and mature brain by regulating neuronal migration and differentiation, neurite outgrowth, axonal fasciculation, synapse formation and synaptic plasticity. CAM-mediated changes in neuronal behavior depend on a number of intracellular signaling cascades including changes in various second messengers, among which CAM-dependent changes in intracellular Ca2+ levels play a prominent role. Ca2+ is an essential secondary intracellular signaling molecule that regulates fundamental cellular functions in various cell types, including neurons. We present a systematic review of the studies reporting changes in intracellular Ca2+ levels in response to activation of the immunoglobulin superfamily CAMs, cadherins and integrins in neurons. We also analyze current experimental evidence on the Ca2+ sources and channels involved in intracellular Ca2+ increases mediated by CAMs of these families, and systematically review the role of the voltage-dependent Ca2+ channels (VDCCs) in neurite outgrowth induced by activation of these CAMs. Molecular mechanisms linking CAMs to VDCCs and intracellular Ca2+ stores in neurons are discussed.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24330678 PMCID: PMC3878801 DOI: 10.1186/1478-811X-11-94
Source DB: PubMed Journal: Cell Commun Signal ISSN: 1478-811X Impact factor: 5.712
An overview of CAMs, activation of which induces an increase in intracellular Ca levels
| | | | | | | |
| NCAM | Fluorimetry/Quin-2AM | Polyclonal NCAM antibodies, 0.4-1 mg/ml | PC12 cells | Verapamil (full inhibition) | [ | |
| Diltiazem (full inhibition) | ||||||
| Nifedipine (no effect) | ||||||
| | Microscopy/Fura-2AM | Synthetic peptide ligand of NCAM ectodomain, 50 μM | PC12-E2 cells | Not tested | [ | |
| | Fluorimetry/Quin-2AM | Fab fragments of monoclonal NCAM antibodies (H28), 0.1-0.2 mg/ml | PC12 cells | No effect | Not tested | [ |
| | Microscopy/Fura-2AM | Polyclonal NCAM antibodies, 0.3-0.5 mg/ml | PC12 cells | Not tested | [ | |
| | Microscopy/Fura-2AM | Monoclonal NCAM antibodies, 0.1 mg/ml | PC12 cells | No effect | Not tested | [ |
| | Microscopy/Fura-2AM | NCAM antibodies, 0.5 mg/ml | Chick ciliary ganglion neurons | No effect | Not tested | [ |
| | Microscopy/Fura-2AM | Polyclonal NCAM antibodies, 0.3-1 mg/ml | Mouse dorsal root ganglion neurons | Not tested | [ | |
| | Microscopy/Fura-2AM | Monoclonal NCAM antibodies, 0.1 mg/ml | Mouse dorsal root ganglion neurons | No effect | Not tested | [ |
| | Microscopy/Fura-2AM | Polyclonal NCAM antibodies, 0.5 mg/ml | Mouse small cerebellar neurons | No effect | Not tested | [ |
| | Microscopy/Fura-2AM | Monoclonal NCAM antibodies, 0.1 mg/ml | Mouse small cerebellar neurons | No effect | Not tested | [ |
| | Microscopy/Fura-2AM | Purified NCAM from mouse brain, 10 μg/ml | Mouse small cerebellar neurons | Not tested | [ | |
| | Microscopy/Fura-2AM | Recombinant fragments of NCAM ectodomain, 0.8 μM | Mouse small cerebellar neurons | Not tested | [ | |
| | Microscopy/Fura-2AM | Monoclonal NCAM antibodies, 30 μg/ml | Mouse cortical neurons (soma) | No effect | Not tested | [ |
| | Microscopy/Fura-2AM | Synthetic peptide ligand of ectodomain NCAM, 54 μM | Rat hippocampal neurons | Not tested | [ | |
| | | Polyclonal NCAM antibodies, 1 mg/ml | Rat hippocampal neurons | Not tested | [ | |
| | Microscopy/ Fura-2AM or Fluo-4AM | Synthetic peptide ligand of NCAM, 12–35 μM | Rat hippocampal neurons (soma) | Nifedipine (partial inhibition) | [ | |
| Mibefradil (partial inhibition) | ||||||
| Pimozide (full inhibition) | ||||||
| ω-conotoxin (no inhibition) | ||||||
| Agatoxin (no inhibition) | ||||||
| Loe908 (partial inhibition) | ||||||
| SKF-96365 (partial inhibition) | ||||||
| L1 | Fluorimetry/Quin-2AM | Polyclonal L1 antibodies, 0.4-1 mg/ml | PC12 cells | Not tested | [ | |
| | Microscopy/Fura-2AM | Polyclonal L1 antibodies, 0.3-1 mg/ml | Mouse dorsal root ganglion neurons | Verapamil (no effect) | [ | |
| Diltiazem (no effect) | ||||||
| Cd2+/Ni2+ (no effect) | ||||||
| | Microscopy/Fura-2AM | Recombinant ectodomain of L1 (L1-Fc), 10 μg/ml | Rat dorsal root ganglion neurons (growth cones) | Nifedipine (full inhibition)a | [ | |
| Conotoxin (partial inhibition)a | ||||||
| | Microscopy/Fura-2 dextran | L1 expressed by 3 T3 cells | Rat dorsal root ganglion neurons (growth cones) | No effect | Not tested | [ |
| | Whole cell patch-clamp | Monoclonal L1 antibodies recognizing glycosylated L1, 7.5-30 μg/ml | Mouse dorsal root ganglion neurons | Nifedipine (full inhibition) | [ | |
| Cd2+ (full inhibition) | ||||||
| | Microscopy/Fura-2 AM | Polyclonal L1 antibodies, 0.3-0.5 mg/ml | Mouse small cerebellar neurons | Verapamil (no effect) | [ | |
| Diltiazem (no effect) | ||||||
| Cd2+/Ni2+ (No effect) | ||||||
| | Fluorimetry/Quin-2AM; Microscopy/Fura2AM | Purified L1 from mouse brain, 10 μg/ml or 0.8 μM | Mouse small cerebellar neurons | Not tested | [ | |
| | Fluorimetry/Quin-2AM | Monoclonal L1 antibodies recognizing FNIII type repeats, 100 μg/ml | Mouse small cerebellar neurons | Not tested | [ | |
| | Fluorimetry/Quin-2AM | Monoclonal L1 antibodies recognizing Ig-like domains I-VI, 100 μg/ml | Mouse small cerebellar neurons | No effect | Not tested | [ |
| | Microscopy/Fura-2AM, | Monoclonal L1 antibodies recognizing glycosylated L1, 7.5-30 μg/ml | Mouse cortical neurons (soma) | Nifedipine (full inhibition) | [ | |
| Whole cell patch-clamp | ||||||
| Cd2+ (full inhibition) | ||||||
| Np55 | Microscopy/Fluo-4AM | Soluble recombinant ectodomain of Np55, 15 μM | Rat hippocampal neurons | Not tested | [ | |
| (synaptic areas) | ||||||
| Np65 | Micriscopy/Fluo-4AM | Soluble recombinant ectodomain of Np65, 15 μM | Rat hippocampal neurons | Not tested | [ | |
| (synaptic areas) | ||||||
| | Micriscopy/Fluo-4AM | Syntetic peptide ligand of Np65 enplastin, 7–15 μM | Rat hippocampal neurons | Not tested | [ | |
| (synaptic areas) | ||||||
| NgCAM | Microscopy/Fluo-3AM; Fura-2AM | Purified chicken NgCAM, 1.2 μg/ml | Neostriatal subependymal zone neurons of adult zebra finch | Nifedipine (full inhibition) | [ | |
| ω-conotoxin (partial inhibition) | ||||||
| | Microscopy/Fluo-3AM; Fura-2AM | Polyclonal NgCAM antibodies, 100 μg/ml | Neostriatal subependymal zone neurons of adult zebra finch | Nifedipine (full inhibition) | [ | |
| ω-conotoxin (partial inhibition) | ||||||
| LAMP | Microscopy/Fluo-3AM | Soluble recombinant LAMP, 30 μg/ml | Rat hippocampal neuron | Nifedipine (full inhibition) | [ | |
| ω-conotoxin (no inhibition) | ||||||
| | Microscopy/Fluo-3AM | Soluble recombinant LAMP, 30 μg/ml | Visual cortex neurons | Not tested | [ | |
| Thy-1 | Microscopy /Fura-2AM | Fab fragments of monoclonal Thy-1 antibodies, 10 μg/ml | PC12 cells (cytosol) | No effect | Not tested | [ |
| | | | | | | |
| N-cadherin | Microscopy/Fura-2AM | Soluble fragments of N-cadherin purified from brain or retina, 10 μg/ml | Chick ciliary ganglion neurons | Mixture of diltiazem and ω-conotoxin (no inhibition) | [ | |
| (soma, growth cones) | ||||||
| | Whole cell voltage clamp | Recombinant ectodomain of N-cadherin (N-cadherin-Fc), 20 μg/ml | Chick ciliary ganglion neurons | Not tested | [ | |
| | Microscopy/Fura-2AM | Soluble recombinant ectodomain of N-cadherin (N-cadherin-Fc), 50 μg/ml | Chick retinal ganglion cells | No effect | Not tested | [ |
| | Microscopy/FFP-18-AM | Soluble recombinant ectodomain of N-cadherin (N-cadherin-Fc), 50 μg/ml | Chick retinal ganglion cells (subplasma membrane of growth cones) | Mixture of nifedipine and ω-conotoxin (partial inhibition) | [ | |
| Celsr2/Celsr3 | Microscopy/Fura-2AM | Soluble recombinant cadherin repeats of Celsr2/Celsr3, 1 μg/ml | Rat hippocampal neurons | Not tested | [ | |
| | | | | | | |
| β Integrin | Microscopy/Fura-2AM, whole cell voltage clamp | RGD peptide (cGRGDSPA), 1 μM | Not tested | [ | ||
| (soma) | ||||||
| | High-speed microscopy/Fluo-4AM | Synthetic RGD peptide (RGDS), 0.5-1 μM | Not tested | [ | ||
| | Microscopy/Fura-2AM | Soluble Laminin, 20 μg/ml | Chick ciliary ganglion neurons (soma) | Mixture of diltiazem and ω-conotoxin (no inhibition) | [ | |
| | Microscopy/Fura-2AM | Laminin, immobilized to the beads, 50 μg/ml | Chick dorsal root ganglion neurons (growth cones) | No effect | Not tested | [ |
| | Microscopy/Fura-2AM | Soluble laminin, 20 μg/ml | Surgically isolated filopodia from growth cones of chick dorsal root ganglion neurons | Not tested | [ | |
| | Microscopy/Fura-2AM | RGD peptide (GRGDSP), 10 μM | Mouse cortical neurons (soma and neurites) | Gd3+ (partial inhibition) | [ | |
| Nifedipine (partial inhibition) | ||||||
| | Whole cell voltage clamp | Polyclonal α5β1 integrin antibodies, 10 μg/ml | Rat basal forebrain neurons | Not tested | [ | |
| Microscopy/Fura-2AM | Syntetic RGD peptide (GRGDSP), 2.5 mM | Rat cortical neurons | Not tested | [ |
aeffect observed in the presence of Ba2+ in the test solution.
CAMs, methods used to detect changes in intracellular Ca2+ levels, Ca2+ sensitive indicator used in optical recordings, ligands used to activate CAMs, cell type analyzed and subcellular localization of Ca2+ changes (if described in the original publication), the effect of CAMs on intracellular Ca2+ levels (↑ - indicates an increase), the effect of inhibitors of Ca2+ channels on CAM-induced intracellular Ca2+ increases, and respective references are listed in the table.
An ovsssserview of the effects of the inhibitors of Ca channels on CAM-mediated neurite outgrowth
| | | | | |
| NCAM | PC12 cells | Diltiazem (L-type VDCCs), ω-conotoxin (N-type VDCCs) | Partial inhibition | [ |
| | | Mixture of diltiazem and ω-conotoxin (L-type and N-type VDCCs) | Full inhibition | [ |
| | Rat hippocampal neurons | Nifedipine, Diltiazem (L-type VDCC) | Partial inhibition | [ |
| | Rat hippocampal neurons | ω-conotoxin (N-type VDCCs) | Partial inhibition | [ |
| | Rat hippocampal neurons | Mixture of diltiazem and ω-conotoxin | Full inhibition | [ |
| (L-type and N-type VDCCs) | ||||
| | Rat hippocampal neurons | ω-agatoxin (P/Q-type VDCCs) | Partial inhibition | [ |
| | Rat hippocampal neurons | Mibefradil or pimozide (T-type VDCCs) | Full inhibition | [ |
| | Rat hippocampal neurons | ω-conotoxin (N-type VDCCs) | No inhibition | [ |
| | Rat hippocampal neurons | Loe908 or SKF-96365 (NSCCs) | Full inhibition | [ |
| L1-CAM | PC12 cells | Verapamil, diltiazem, nifedipine or ω-conotoxin (L-type or N-type VDCCs) | Partial inhibition | [ |
| | PC12 cells | Mixture of L-type and N-type VDCCs inhibitors | Full inhibition | [ |
| | Rat dorsal root ganglion neurons | ω-conotoxin or verapamil (N-type or L-type VDCCs inhibitors) | Full inhibition | [ |
| | Rat cerebellar neurons | Verapamil, diltiazem, nifedipine or ω-conotoxin (L-type or N-type VDCCs) | Partial inhibition | [ |
| | Rat cerebellar neurons | Mixture of L-type and N-type VDCCs inhibitors | Full inhibition | [ |
| | Mouse small cerebellar neurons | Verapamil, diltiazem, or nifedipine | Partial inhibition | [ |
| (L-type VDCCs) | ||||
| CHL1 | Mouse hippocampal neurons | Nifedipine (L-type VDCCs) | Full inhibition | [ |
| | Mouse hippocampal neurons | Pimozide (T-type VDCCs) | Full inhibition | [ |
| Thy-1 | PC12 cells | Diltiazem, nifedipine, verapamil or ω-conotoxin (L-type or N-type VDCCs) | Full inhibition | [ |
| LAMP | Rat hippocampal neurons | Nifedipine (L-type VDCCs) | Partial inhibition | [ |
| | Rat hippocampal neurons | ω-conotoxin (N-type VDCCs) | No inhibition | [ |
| N-cadherin | PC12 cells | Diltiazem (L-type VDCCs), ω-conotoxin (N-type VDCCs) | Partial inhibition | [ |
| | PC12 cells | Mixture of diltiazem and ω-conotoxin (L-type and N-type VDCCs) | Partial inhibition | [ |
| | Chick ciliary ganglion neurons | Mixture of diltiazem and ω-conotoxin (L-type and N-type VDCCs) | No inhibition | [ |
| β Integrin | Chick ciliary ganglion neurons | Mixture of diltiazem and ω-conotoxin (L-type and N-type VDCCs) | No inhibition | [ |
CAMs and cell type analyzed, inhibitors used and the impact of the inhibitors on the CAM-dependent neurite outgrowth are described.
Figure 1Schematic representation of the possible mechanisms utilized by CAMs to induce an increase in the intracellular Calevels. IgSF CAMs (A), cadherins (B), and integrins (C) can influence intracellular Ca2+ levels by inducing intracellular signaling cascades converging on VDCCs or inducing Ca2+ release from the internal stores (solid arrows). Known intermediate enzymes involved are also shown. Dashed arrows represent proposed pathways, which have not been experimentally analyzed yet. See text for details and references. FGFR - fibroblast growth factor receptor; VDCC - voltage dependent calcium channels with α1, α2, β, γ, and δ denoting the subunits of VDCC; Gα, Gβ, and Gγ - subunits of the G-protein; PLC - phospholipase C; DAG - diacylycerol; AA - arachidonic acid; PKC - protein kinase C; Src - Src-family tyrosine kinase; PKA - protein kinase A; CaMKII - calcium/calmodulin-dependent kinase II; PIP2 - phosphatidylinositol 4, 5-bisphosphate; IP3 - inositol 1,4,5-triphosphate; IP3R - inositol triphosphate receptor; PKA - protein kinase A; RhoA – Ras homolog gene family A; RyR - ryanodine receptor; ER - endoplasmic reticulum.